Allergy Vaccine Market Size was valued at USD 1.47 Billion in 2022. The Allergy vaccine market industry is projected to grow from USD 1.54 Billion in 2023 to USD 3.82 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.7% during the forecast period (2023 - 2032). Rising incidence of allergies, increasing awareness about allergies, advances in allergy vaccine technology, limited efficacy of symptomatic treatment, desire for long-term relief, pediatric allergy management, are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The market for allergy treatments is expanding as a result of the growing public awareness of allergies. Allergies have drawn a lot of attention recently, both from the medical establishment and from the general public. The landscape of allergy management and therapy is changing as a result of the cascade of impacts brought on by this increased awareness.
Numerous platforms, such as the internet, social media, health campaigns, and educational programs run by healthcare institutions, have helped spread awareness of allergies. A plethora of information regarding allergies is available online, on medical websites, and in patient forums, allowing people to better understand their problems and choose whether or not to seek medical attention. As a result, the patient base is becoming more driven to treat their allergies and enhance their quality of life.
Additionally, awareness has prompted earlier allergy management intervention. In the past, people might have just used over-the-counter drugs to treat their symptoms of allergies, considering them to be minor inconveniences. However, as awareness has increased, more individuals are becoming aware of the possible effects that untreated allergies may have on their general health and wellbeing. This has led people to seek medical advice from professionals early, leading to more effective and thorough management options, such as thinking about allergy vaccinations as a long-term fix.
The treatment paradigm for allergy vaccinations has changed as a result of increased awareness. Allergy vaccines, commonly referred to as allergen immunotherapy or allergy shots, work to change how the immune system reacts to allergens, offering long-lasting symptom alleviation and possibly lowering the need for continuous symptom treatment. As more people become aware of this alternative for treatment, they are choosing a more pro-active and long-lasting method of allergy management. The need for individualized, patient-centered treatment has increased as a result of the growing discussion regarding allergies. Patients can now communicate with healthcare professionals more effectively about their symptoms, risk factors, and preferred treatments. As allergy vaccines may be tailored to target individual allergens that are pertinent to each patient's sensitivity, they are especially important for fostering a collaborative approach to treatment decisions. Thus, driving the Allergy vaccine market revenue.
The Allergy vaccine market segmentation, based on type, includes Subcutaneous Immunotherapy and Sublingual Immunotherapy. The subcutaneous immunotherapy segment dominated the market in 2022. This is because SCIT is the more effective form of allergy vaccine therapy and is typically used to treat allergies to pollen, dust mites, and insect stings. These are the most common types of allergies, so there is a large demand for SCIT.
The Allergy vaccine market segmentation, based on Application, includes Allergic Rhinitis, Allergic Asthma and Others. The allergic rhinitis segment dominated the market in 2022. This is because allergic rhinitis, which affects an estimated 10% of people worldwide, is the most widespread type of allergies. Sneezing, runny nose, itchy eyes, and congestion are some of the symptoms of allergic rhinitis. By making the body less sensitive to the allergens responsible for the symptoms, allergy vaccinations can be used to treat allergic rhinitis.
The Allergy vaccine market segmentation, based on distribution channel, includes Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. The hospital pharmacies category generated the most income in 2022. This is due to the fact that hospital pharmacies are the main sellers of allergy shots. They are equipped with the knowledge and tools necessary to safely and successfully give allergy vaccinations. Hospital pharmacies are also frequently compensated by insurance providers, which makes them a more cost-effective choice for consumers.
Figure 1: Allergy Vaccine Market, by Distribution channel, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Allergy Vaccine Market dominated this market in 2022 (45.80%). The area has a strong healthcare infrastructure, including established hospitals, laboratories, and medical personnel with expertise in allergy and immunology. This infrastructure makes it easier to acquire cutting-edge therapeutics like allergy vaccinations as well as allergy testing and treatment. Further, the U.S. Allergy vaccine market held the largest market share, and the Canada Allergy vaccine market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: ALLERGY VACCINE MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Allergy vaccine market accounts for the second-largest market share. The prevalence of allergic conditions such allergic rhinitis, asthma, and food allergies has significantly increased throughout Europe. The need for allergy vaccines is being driven by the increased need for effective and long-lasting treatment alternatives as a result of the high prevalence of allergies. Further, the German Allergy vaccine market held the largest market share, and the UK Allergy vaccine market was the fastest growing market in the European region.
The Asia-Pacific Allergy Vaccine Market is expected to grow at the fastest CAGR from 2023 to 2032. In some areas of the Asia Pacific region, urbanization and industrialization have increased exposure to air pollution and environmental allergies. As a result, allergy disorders are more common, and people are more aware of how these factors affect their health, which has raised interest in cutting-edge treatment alternatives. Moreover, China’s Allergy vaccine market held the largest market share, and the Indian Allergy vaccine market was the fastest growing market in the Asia-Pacific region.
Allergy vaccine Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Allergy vaccine market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Allergy vaccine industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Allergy vaccine industry to benefit clients and increase the market sector. In recent years, the Allergy vaccine industry has offered some of the most significant advantages to medicine. Major players in the Allergy vaccine market, including ALK (Denmark), Stallergenes Greer (Switzerland), Allergy Therapeutics (U.K.), HAL Allergy B.V. (Netherlands), HollisterStier Allergy (U.S.), Zhejiang Wolwo Bio-pharmaceutical Co., Ltd (China), LETIPharma (Spain), Dermapharm Holding SE (Germany) and others, are attempting to increase market demand by investing in research and development operations.
ALK-Abello AS (ALK), a branch of The Lundbeck Foundation, discovers, develops, and commercializes immunotherapies for the management and prevention of allergies. The company's portfolio of allergy immunotherapy treatments, which include tablets, sublingual or drop-based vaccinations, subcutaneous vaccines, and adrenaline auto-injectors, is intended to treat severe allergic reactions in life-threatening conditions (anaphylaxis). ALK is working on developing sublingual immunotherapy pills to treat ragweed, home dust mite, and tree pollen allergies. Ragweed, home dust mites, Japanese cedar, grass, trees, and venom are among the allergens that the company's remedies are designed to cure. The company has affiliates in Europe, Asia-Pacific, and North America. ALK's headquarters are in Horsholm, Denmark.
Medication for both allergy treatment and allergy prevention is produced by a specialty pharmaceutical company called Allergy Therapeutics Plc (Allergy Therapeutics). The company offers a wide range of aluminum-free allergy vaccines and tests. Allergy Therapeutics sells a variety of treatments, including Bee Venom Subcutaneous Immunotherapy (SCIT), Wasp Venom SCIT, Tree MATA, and Grass Modified Allergen Tyrosine Adsorbed (MATA). It additionally offers allergen extracts for skin prick testing. The business sells a range of diagnostic products, such as pollen, molds, insects, and epithelia. It also runs businesses in the Netherlands, the United Kingdom, Austria, Switzerland, Germany, Italy, and Spain. The company's headquarters are in Worthing, West Sussex, in the United Kingdom.
Key Companies in the Allergy vaccine market include
ALK (Denmark)
Stallergenes Greer (Switzerland)
Allergy Therapeutics (U.K.)
HAL Allergy B.V. (Netherlands)
HollisterStier Allergy (U.S.)
Zhejiang Wolwo Bio-pharmaceutical Co., Ltd (China)
LETIPharma (Spain)
Dermapharm Holding SE (Germany)
Allergy vaccine Industry Developments
January 2023:The allergy market was first introduced to Ultrafiltered Dog, HollisterStier Allergy's most recent product innovation. Patients who are sensitive to dogs can be diagnosed and treated with success with this medicine.
January 2023:The ALK’s ODACTRA has received US Food and Drug Administration approval for the treatment of house dust mite (HDM)-induced allergic rhinitis.
Subcutaneous Immunotherapy
Sublingual Immunotherapy
Allergic Rhinitis
Allergic Asthma
Others
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 1.47 Billion |
| Market Size 2023 | USD 1.54 Billion |
| Market Size 2032 | USD 3.82 Billion |
| Compound Annual Growth Rate (CAGR) | 9.7% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application, Distribution Channel, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | ALK (Denmark), Stallergenes Greer (Switzerland), Allergy Therapeutics (U.K.), HAL Allergy B.V. (Netherlands), HollisterStier Allergy (U.S.), Zhejiang Wolwo Bio-pharmaceutical Co., Ltd (China), LETIPharma (Spain), Dermapharm Holding SE (Germany) |
| Key Market Opportunities | Clinical trials and ongoing research aimed at enhancing the effectiveness, safety, and practicality of allergy vaccinations. |
| Key Market Dynamics | Greater understanding of allergens and how they affect health and quality of life |
Allergy Vaccine Market Highlights:
Frequently Asked Questions (FAQ) :
The Allergy vaccine market size was valued at USD 1.47 Billion in 2022.
The market is projected to grow at a CAGR of 9.7% during the forecast period, 2023-2032.
North America had the largest share in the market
The key players in the market are ALK (Denmark), Stallergenes Greer (Switzerland), Allergy Therapeutics (U.K.), HAL Allergy B.V. (Netherlands), HollisterStier Allergy (U.S.), Zhejiang Wolwo Bio-pharmaceutical Co., Ltd (China), LETIPharma (Spain), Dermapharm Holding SE (Germany).
The Subcutaneous Immunotherapy category dominated the market in 2022.
The Hospital Pharmacies had the largest share in the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
